TRINETRA › Sectors › Chemicals
Sudeep Pharma Limited (SUDEEPPHRM) — share price, P/E and fundamentals
Sudeep Pharma Limited (NSE: SUDEEPPHRM) closed at ₹1,068.30 on 30 Oct 2026, against a 52-week range of ₹524.05 – ₹1,378.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 28 Oct 2026) it reported revenue of ₹197 cr and net profit of ₹52 cr, a 26.3% net margin; revenue grew 20.9% and profit grew 19.3% year on year.
On four consecutive filed quarters its trailing P/E is 63.9.
From the balance sheet dated 30 Sept 2026: return on equity 21.7%, ROCE 27.4%, debt-to-equity 0.20, Piotroski F-score 5 of 9.
Against 42 Chemicals peers on NSE: Net margin higher than 95% of 42 sector peers; PBT margin higher than 95% of 42 sector peers; ROE higher than 82% of 40 sector peers.
Key figures
| Last close | ₹1,068.30 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -6.6% / +56.7% / — |
| 52-week low – high | ₹524.05 – ₹1,378.00 |
| Market capitalisation | ₹12,059 cr |
| Trailing P/E | 63.9 |
| Price / book | 12.60 |
| EV / EBITDA | 44.3 |
| Earnings yield | 1.6% |
| TTM EPS | ₹16.71 |
| TTM net profit | ₹189 cr |
| Quarter revenue | ₹197 cr |
| Quarter net profit | ₹52 cr |
| Net margin | 26.3% |
| Revenue growth (YoY) | +20.9% |
| Profit growth (YoY) | +19.3% |
| Return on equity | 21.7% |
| ROCE | 27.4% |
| Debt / equity | 0.20 |
| Current ratio | 2.91 |
| Free cash flow | ₹43 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹23.6 cr |
Against Chemicals peers
| Metric | SUDEEPPHRM | Peer median | Percentile |
|---|---|---|---|
| Net margin | 26.34 | 9.91 | 95 |
| PBT margin | 36.11 | 13.29 | 95 |
| ROE | 21.65 | 13.64 | 83 |
| ROCE | 27.36 | 16.08 | 88 |
| Debt / equity | 0.20 | 0.26 | 45 |
| FCF margin | 12.20 | -0.57 | 92 |
| Cash conversion | 0.47 | 0.95 | 35 |
| Trailing P/E | 63.93 | 33.95 | 81 |
Questions
What is the P/E ratio of Sudeep Pharma Limited?
Sudeep Pharma Limited's trailing P/E is 63.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026.
What were Sudeep Pharma Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Sudeep Pharma Limited reported revenue of ₹197 cr and net profit of ₹52 cr (consolidated), filed with the exchange on 28 Oct 2026.
What is Sudeep Pharma Limited's ROE?
Return on equity is 21.7% based on the balance sheet dated 30 Sept 2026.
Does Sudeep Pharma Limited have debt?
Debt-to-equity is 0.20 on the balance sheet dated 30 Sept 2026.
What is SUDEEPPHRM's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SUDEEPPHRM traded between ₹524.05 and ₹1,378.00.
Other Chemicals stocks
- Solar Industries India Limited (SOLARINDS)
- Pidilite Industries Limited (PIDILITIND)
- SRF Limited (SRF)
- Coromandel International Limited (COROMANDEL)
- Linde India Limited (LINDEINDIA)
- Gujarat Fluorochemicals Limited (FLUOROCHEM)
- Navin Fluorine International Limited (NAVINFLUOR)
- Fertilizers and Chemicals Travancore Limited (FACT)
- UPL Limited (UPL)
- Himadri Speciality Chemical Limited (HSCL)
- Aether Industries Limited (AETHER)
- Deepak Nitrite Limited (DEEPAKNTR)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.